TY-9591

DRUG3 trials

Sponsors

TYK Medicines, Inc

Conditions

Brain MetastasesEGFR Activating MutationHealthy VolunteersNSCLC

Phase 1

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

CompletedNCT05871905

TYK Medicines, IncHealthy Volunteers

Start: 2023-06-19End: 2024-06-20Updated: 2024-12-30

Phase 2

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

RecruitingNCT05948813

TYK Medicines, IncBrain Metastases, EGFR Activating Mutation, NSCLC

Start: 2023-08-17End: 2030-03-30Target: 420Updated: 2026-08-25

Phase 3

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

RecruitingNCT05382728

TYK Medicines, IncEGFR Activating Mutation, NSCLC

Start: 2022-06-08End: 2027-12-31Target: 680Updated: 2024-01-30

Related Papers

Efficacy and safety of asandeutertinib versus osimertinib as first-line treatment in EGFR-mutated NSCLC patients with brain metastases: Interim analysis of an open-label, multicenter, randomized, pivotal phase II study (ESAONA).

Journal of Clinical Oncology2026-06-03

A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.

Journal of Clinical Oncology2025-05-28

Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <i>in vitro</i> and <i>in vivo</i>

Cancer Research2023-04-043 citations